EZH2 and prostate cancer: A key study in castration‐resistant prostate cancer revealed that EZH2 promoted tumorigenicity by acting as a cofactor to other transcription factors rather than canonically facilitating H3K27me3 modification, further supporting the notion that inhibiting EZH2 could elicit phenotypes independent of H3K27me3.81